List view / Grid view
9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
8 June 2012 | By Novo Nordisk
Regulatory review period extended for insulins degludec & insulin degludec/insulin aspart...
Tecan has signed a co-marketing agreement with Reinnervate, a leading company in the 3D cell culture market, to develop a range of automated solutions based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
7 June 2012 | By Publicis Life Brands Resolute
New efficacy and safety data...
7 June 2012 | By Phenomenex Inc
Phenomenex proudly marks its 30th anniversary in 2012...
7 June 2012 | By GlaxoSmithKline
The US FDA has approved Horizant® (gabapentin enacarbil)...
6 June 2012 | By BASF
Metanomics Health GmbH is launching MetaMap®Tox...
6 June 2012 | By Roche
Data announced from the ADACTA study...
6 June 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company have announced the results of AMPLE...
6 June 2012 | By Novartis
New data announced from two trials...
6 June 2012 | By Eli Lilly and Company
The Board of Directors of Eli Lilly and Company has elected William G. Kaelin Jr., M.D. as a new member...
6 June 2012 | By Abbott
First Phase 3 study to evaluate an anti-TNF in patients with non-radiographic axial spondyloarthritis...
6 June 2012 | By Abbott
Abbott announced results from two long-term, open-label studies...
